Amplitude Surgical – H1 2020-21: Sales down 5.3% at Constant Exchange Rates
18 Febbraio 2021 - 6:00PM
Business Wire
- Consolidated sales of €45.9 million, -5.3% at constant exchange
rates
- Activity impacted by the COVID-19 pandemic: France -2.6%,
International -9.6% at constant exchange rates
- Further growth in Novastep’s activity: +25.1% at constant
exchange rates
Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible
for PEA-PME plans) (“Amplitude” or the “Group”)
(Paris:AMPLI), leading French player on the global surgical
technology market for lower-limb orthopedics, announces its sales
for the first half of its 2020-21 financial year.
Olivier Jallabert, Amplitude Surgical’s CEO, commented:
“In the first half of our 2020-21 financial year, Amplitude
Surgical’s activity was impacted, in the second quarter, by the
deterioration in the public health situation associated with
COVID-19 on the majority of its markets and by the adoption of
restrictions on access to operating rooms. As a result, the Group’s
activity was down by 5.3% at constant exchange rates compared with
the previous year. Novastep has continued its development, and now
accounts for approximately 13% of Group sales, with growth of
almost 25% at constant exchange rates. Despite the COVID-19 impact,
the Group is in a solid financial position and intends to seize any
external growth opportunities by looking into openings to acquire
rival companies or agents”.
H1 2020-21
sales
6 months to 31/12/2020
6 months to 31/12/2019
Change at current exchange
rates
Change at constant
exchange rates
In €k - IFRS
France
29,615
30,404
-2.6%
-2.6%
International
16,295
19,429
-16.1%
-9.6%
o/w subsidiaries
12,457
14,363
-13.3%
-4.4%
o/w distributors
3,839
5,066
-24.2%
-24.3%
Total
45,910
49,833
-7.9%
-5.3%
Q2 2020-21
sales
3 months to 31/12/2020
3 months to 31/12/2019
Change at current exchange
rates
Change at constant exchange
rates
In €k - IFRS
France
15,468
18,313
-15.5%
-15.5%
International
8,859
10,684
-17.1%
-10.4%
o/w subsidiaries
6,938
7,549
-8.1%
1.3%
o/w distributors
1,921
3,136
-38.7%
-38.7%
Total
24,327
28,997
-16.1%
-13.7%
Over the first half of its 2020-21 financial year (from July to
December 2020), Amplitude Surgical recorded sales of €45.9 million,
down 7.9% in actual terms and 5.3% at constant exchange rates.
- On the French market, Amplitude Surgical recorded a 2.6%
fall in H1 sales to €29.6 million, impacted by the second wave of
the COVID-19 pandemic in the second quarter of the Group’s
financial year (October – December 2020) and the adoption of
restrictions on access to operating rooms from October 2020. France
accounted for 64% of total sales;
- The Group’s international activity generated sales of
€16.3 million, down 16.1% in actual terms and 9.6% at constant
exchange rates. The Group’s subsidiaries recorded a 13.3% decrease
in sales to €12.5 million, subsidiaries’ activity notably being
impacted by the public health situation associated with COVID-19 in
Brazil, Germany and Australia. Activity with distributors also
weakened, falling 24.2% to €3.8 million;
- Amplitude Surgical’s direct business (French market and
international subsidiaries), which accounted for close to 92% of
the Group’s total sales, slipped 3.1% at constant exchange
rates;
- Sales generated by Novastep, innovative solutions for
foot and ankle surgery, continued to grow in the first half and
totaled €6.1 million (+25.1% at constant exchange rates), driven by
the United States (+42.0% at constant exchange rates). Novastep now
accounts for approximately 13% of the Group’s sales.
Next press release H1 2020-21 results, on Wednesday March 24,
2021, after market.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a
leading French player on the global surgical technology market for
lower-limb orthopedics. Amplitude Surgical develops and markets
high-end products for orthopedic surgery covering the main
disorders affecting the hip, knee and extremities, and notably foot
and ankle surgery. Amplitude Surgical develops, in close
collaboration with surgeons, numerous high value-added innovations
in order to best meet the needs of patients, surgeons and
healthcare facilities. A leading player in France, Amplitude
Surgical is developing abroad through its subsidiaries and a
network of exclusive distributors and agents distributing its
products in more than 30 countries. Amplitude Surgical operates on
the lower-limb market through the intermediary of its Novastep
subsidiaries in France and the United States. At June 30, 2020,
Amplitude Surgical had a workforce of 436 employees and recorded
sales of nearly 88 million euros.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210218005500/en/
Amplitude Surgical Dimitri Borchtch CFO finances@amplitude-surgical.com
+33 (0)4 75 41 87 41
NewCap Investor
Relations Mathilde
Bohin/Thomas Grojean amplitude@newcap.eu +33 (0)1 44 71 94
94
NewCap Media
Relations Nicolas
Merigeau amplitude@newcap.eu +33 (0)1 44 71 94 98
Grafico Azioni Amplitude Surgical (EU:AMPLI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Amplitude Surgical (EU:AMPLI)
Storico
Da Apr 2023 a Apr 2024